Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Inventory (2016 - 2025)

Corcept Therapeutics' Inventory history spans 10 years, with the latest figure at $12.3 million for Q2 2025.

  • For Q2 2025, Inventory rose 47.02% year-over-year to $12.3 million; the TTM value through Jun 2025 reached $12.3 million, up 47.02%, while the annual FY2024 figure was $12.4 million, 60.57% up from the prior year.
  • Inventory for Q2 2025 was $12.3 million at Corcept Therapeutics, down from $14.4 million in the prior quarter.
  • Across five years, Inventory topped out at $14.4 million in Q1 2025 and bottomed at $4.9 million in Q1 2021.
  • The 5-year median for Inventory is $7.1 million (2023), against an average of $7.9 million.
  • The largest annual shift saw Inventory rose 1.59% in 2021 before it soared 99.83% in 2025.
  • A 5-year view of Inventory shows it stood at $5.0 million in 2021, then rose by 22.29% to $6.1 million in 2022, then increased by 26.72% to $7.7 million in 2023, then skyrocketed by 60.57% to $12.4 million in 2024, then fell by 1.1% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Inventory are $12.3 million (Q2 2025), $14.4 million (Q1 2025), and $12.4 million (Q4 2024).